Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 21 Jul 2023

Cicali Emily J, Elchynski Amanda, Thomas Cameron D, Alam Benish, Dalton Rachel, Davis Rick, Eken Eda, Estores David, Nguyen Khoa, Cavallari Larisa H, Wiisanen Kristin

Abstract excerpt

PURPOSE: To describe the implementation of CYP2C19 testing into clinical practice at University of Florida (UF) Health Gainesville hospital to guide proton pump inhibitor (PPI) dosing and the lessons learned from this experience. SUMMARY: Different CYP2C19 genotypes are associated with variability in PPI plasma concentrations and intragastric pH, which may contribute to the risk of treatment failure due to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Pharmacogenetics

Share to Precision Medicine

Share to Proton Pump Inhibitors

Source

Identifiers

PMID: 37166240
DOI: 10.1093/ajhp/zxad099

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center.PMID 37166240Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.Semantic proximity Read ↗

Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice.Semantic proximity Read ↗

CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use.Semantic proximity Read ↗

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Semantic proximity Read ↗

Clinical pharmacogenetics implementation: approaches, successes, and challenges.Semantic proximity Read ↗

New Guidance on Cytochrome P450 2C19 Phenotype-based Use of Proton Pump Inhibitors.Semantic proximity Read ↗

Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult ClinicSemantic proximity Read ↗

CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections.Semantic proximity Read ↗

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.Semantic proximity Read ↗

Prevalence of CYP2C19 polymorphisms in medically and surgically managed patients with GERD.Semantic proximity Read ↗

Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.Semantic proximity Read ↗

Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.